Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin

Andrés Poveda, Isabelle Ray-Coquard, Ignacio Romero, Jose Antonio Lopez-Guerrero, Nicoletta Colombo

Research output: Contribution to journalArticle

Abstract

Ovarian cancer (OC) is the leading cause of death from gynecological malignancies. In spite of high response rates to the standard front-line treatment for advanced disease with cytoreductive surgical debulking, followed by platinum/taxane-based chemotherapy, most patients eventually relapse developing drug-resistant disease. Owing to the molecular heterogeneity, genetic instability and mutagenicity of OC, increases in survival might be achieved by translating recent insights at the morpho-molecular levels to individual therapeutic strategies. Several emerging treatments have been shown to be active in platinum-sensitive (PS) recurrent OC (ROC), but an optimal strategy still has not been established. Based on the recent results, it is likely that the introduction of novel non-platinum based chemotherapies and molecular targeted therapies will have a major impact on the management of ROC. Some current strategies are focused on the extension of platinum-free interval (PFI) in patients with PS, particularly in those with partially PS disease. Apparently, the PFI extension by an effective non-platinum intervention, such as trabectedin plus pegylated liposomal doxorubicin (PLD), may reduce cumulative platinum-induced toxicities leading to longer survival after the reintroduction of subsequent platinum. The introduction of novel therapies, such as the antiangiogenic monoclonal antibody bevacizumab, opens a new field of targeted therapies in this indication. In this review, we aim to outline the therapeutic potential of new emerging approaches, particularly the role of non-platinum therapy with trabectedin in combination with PLD in patients with PS ROC.

Original languageEnglish
Pages (from-to)366-375
Number of pages10
JournalCancer Treatment Reviews
Volume40
Issue number3
DOIs
Publication statusPublished - Apr 2014

Fingerprint

trabectedin
Platinum
Ovarian Neoplasms
Therapeutics
Molecular Targeted Therapy
Drug Therapy
Survival

Keywords

  • Platinum-sensitive
  • PLD
  • Recurrent ovarian cancer
  • Trabectedin

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer : Focus on trabectedin. / Poveda, Andrés; Ray-Coquard, Isabelle; Romero, Ignacio; Lopez-Guerrero, Jose Antonio; Colombo, Nicoletta.

In: Cancer Treatment Reviews, Vol. 40, No. 3, 04.2014, p. 366-375.

Research output: Contribution to journalArticle

Poveda, Andrés ; Ray-Coquard, Isabelle ; Romero, Ignacio ; Lopez-Guerrero, Jose Antonio ; Colombo, Nicoletta. / Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer : Focus on trabectedin. In: Cancer Treatment Reviews. 2014 ; Vol. 40, No. 3. pp. 366-375.
@article{d7264c18133f48ed8c8c219ef064c3c7,
title = "Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin",
abstract = "Ovarian cancer (OC) is the leading cause of death from gynecological malignancies. In spite of high response rates to the standard front-line treatment for advanced disease with cytoreductive surgical debulking, followed by platinum/taxane-based chemotherapy, most patients eventually relapse developing drug-resistant disease. Owing to the molecular heterogeneity, genetic instability and mutagenicity of OC, increases in survival might be achieved by translating recent insights at the morpho-molecular levels to individual therapeutic strategies. Several emerging treatments have been shown to be active in platinum-sensitive (PS) recurrent OC (ROC), but an optimal strategy still has not been established. Based on the recent results, it is likely that the introduction of novel non-platinum based chemotherapies and molecular targeted therapies will have a major impact on the management of ROC. Some current strategies are focused on the extension of platinum-free interval (PFI) in patients with PS, particularly in those with partially PS disease. Apparently, the PFI extension by an effective non-platinum intervention, such as trabectedin plus pegylated liposomal doxorubicin (PLD), may reduce cumulative platinum-induced toxicities leading to longer survival after the reintroduction of subsequent platinum. The introduction of novel therapies, such as the antiangiogenic monoclonal antibody bevacizumab, opens a new field of targeted therapies in this indication. In this review, we aim to outline the therapeutic potential of new emerging approaches, particularly the role of non-platinum therapy with trabectedin in combination with PLD in patients with PS ROC.",
keywords = "Platinum-sensitive, PLD, Recurrent ovarian cancer, Trabectedin",
author = "Andr{\'e}s Poveda and Isabelle Ray-Coquard and Ignacio Romero and Lopez-Guerrero, {Jose Antonio} and Nicoletta Colombo",
year = "2014",
month = "4",
doi = "10.1016/j.ctrv.2013.08.001",
language = "English",
volume = "40",
pages = "366--375",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer

T2 - Focus on trabectedin

AU - Poveda, Andrés

AU - Ray-Coquard, Isabelle

AU - Romero, Ignacio

AU - Lopez-Guerrero, Jose Antonio

AU - Colombo, Nicoletta

PY - 2014/4

Y1 - 2014/4

N2 - Ovarian cancer (OC) is the leading cause of death from gynecological malignancies. In spite of high response rates to the standard front-line treatment for advanced disease with cytoreductive surgical debulking, followed by platinum/taxane-based chemotherapy, most patients eventually relapse developing drug-resistant disease. Owing to the molecular heterogeneity, genetic instability and mutagenicity of OC, increases in survival might be achieved by translating recent insights at the morpho-molecular levels to individual therapeutic strategies. Several emerging treatments have been shown to be active in platinum-sensitive (PS) recurrent OC (ROC), but an optimal strategy still has not been established. Based on the recent results, it is likely that the introduction of novel non-platinum based chemotherapies and molecular targeted therapies will have a major impact on the management of ROC. Some current strategies are focused on the extension of platinum-free interval (PFI) in patients with PS, particularly in those with partially PS disease. Apparently, the PFI extension by an effective non-platinum intervention, such as trabectedin plus pegylated liposomal doxorubicin (PLD), may reduce cumulative platinum-induced toxicities leading to longer survival after the reintroduction of subsequent platinum. The introduction of novel therapies, such as the antiangiogenic monoclonal antibody bevacizumab, opens a new field of targeted therapies in this indication. In this review, we aim to outline the therapeutic potential of new emerging approaches, particularly the role of non-platinum therapy with trabectedin in combination with PLD in patients with PS ROC.

AB - Ovarian cancer (OC) is the leading cause of death from gynecological malignancies. In spite of high response rates to the standard front-line treatment for advanced disease with cytoreductive surgical debulking, followed by platinum/taxane-based chemotherapy, most patients eventually relapse developing drug-resistant disease. Owing to the molecular heterogeneity, genetic instability and mutagenicity of OC, increases in survival might be achieved by translating recent insights at the morpho-molecular levels to individual therapeutic strategies. Several emerging treatments have been shown to be active in platinum-sensitive (PS) recurrent OC (ROC), but an optimal strategy still has not been established. Based on the recent results, it is likely that the introduction of novel non-platinum based chemotherapies and molecular targeted therapies will have a major impact on the management of ROC. Some current strategies are focused on the extension of platinum-free interval (PFI) in patients with PS, particularly in those with partially PS disease. Apparently, the PFI extension by an effective non-platinum intervention, such as trabectedin plus pegylated liposomal doxorubicin (PLD), may reduce cumulative platinum-induced toxicities leading to longer survival after the reintroduction of subsequent platinum. The introduction of novel therapies, such as the antiangiogenic monoclonal antibody bevacizumab, opens a new field of targeted therapies in this indication. In this review, we aim to outline the therapeutic potential of new emerging approaches, particularly the role of non-platinum therapy with trabectedin in combination with PLD in patients with PS ROC.

KW - Platinum-sensitive

KW - PLD

KW - Recurrent ovarian cancer

KW - Trabectedin

UR - http://www.scopus.com/inward/record.url?scp=84892860463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892860463&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2013.08.001

DO - 10.1016/j.ctrv.2013.08.001

M3 - Article

C2 - 24296108

AN - SCOPUS:84892860463

VL - 40

SP - 366

EP - 375

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 3

ER -